ReviewJournal of cancer research and clinical oncology2020
Separating or combining immune checkpoint inhibitors (ICIs) and radiotherapy in the treatment of NSCLC brain metastases.
Review in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04835025 (A Retrospective, Multicenter Case-control Study of Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer), which is not on this map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Retrospective, Multicenter Case-control Study of Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Different detection rates of brain metastasis in different pathological types of lung cancer byBMC cancer · 2025Article
- Research progress on immunotherapy combined with neoadjuvant concurrent chemoradiotherapy in pMMR/MSS locally advanced rectal cancer.Frontiers in immunology · 2025Review
- Hematological parameters as predictors of immune-related adverse events: risk factor analysis in non-small cell lung cancer patients undergoing immunotherapy.American journal of translational research · 2025Article
- Immuno-inflammatory signature for predicting therapeutic response and survival after stereotactic radiosurgery in NSCLC patients with brain metastases: a retrospective cohort study.Frontiers in immunology · 2025Article
- A retrospective cohort study of neoadjuvant chemoradiotherapy combined with immune checkpoint inhibitors in locally advanced rectal cancer.Translational oncology · 2024Article
- Penpulimab and Anlotinib in PDL1 high-expression pulmonary giant cell carcinoma with cerebral metastases: case report and review.Frontiers in oncology · 2024Article
- Prognostic value of cell-free DNA in cerebrospinal fluid from lung cancer patients with brain metastases during radiotherapy.Radiation oncology (London, England) · 2023Article
- Integrated analysis reveals the microenvironment of non-small cell lung cancer and a macrophage-related prognostic model.Translational lung cancer research · 2023Article
- Radiotherapy combined with PD-1/PD-L1 inhibitors in NSCLC brain metastases treatment: The mechanisms, advances, opportunities, and challenges.Cancer medicine · 2023Review
- Primary systemic therapy for patients with brain metastases from lung cancer ineligible for targeted agents.Journal of cancer research and clinical oncology · 2022Article
- Human umbilical vein endothelial cells-derived microRNA-203-containing extracellular vesicles alleviate non-small-cell lung cancer progression through modulating the DTL/p21 axis.Cancer gene therapy · 2022Article
- Combinations of radiotherapy with immunotherapy in cervical cancer.Journal of Cancer · 2022Review
- Improved Survival With Surgical Treatment of Primary Lung Lesions in Non-Small Cell Lung Cancer With Brain Metastases: A Propensity-Matched Analysis of Surveillance, Epidemiology, and End Results Database.Frontiers in oncology · 2022Article
- Zebrafish xenograft model for studying mechanism and treatment of non-small cell lung cancer brain metastasis.Journal of experimental & clinical cancer research : CR · 2021Article
- Is there any opportunity for immune checkpoint inhibitor therapy in non-small cell lung cancer patients with brain metastases?Translational lung cancer research · 2021Review
- microRNA-let-7e in serum-derived exosomes inhibits the metastasis of non-small-cell lung cancer in a SUV39H2/LSD1/CDH1-dependent manner.Cancer gene therapy · 2021Article
- Radiation Plus Anti-PD-1 Therapy for NSCLC Brain Metastases: A Retrospective Study.Frontiers in oncology · 2021Article
- Combination of Immune Checkpoint Inhibitors and Anti-Angiogenic Agents in Brain Metastases From Non-Small Cell Lung Cancer.Frontiers in oncology · 2021Review
- [Research Progress in the Treatment of Brain Metastases from Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
With the advancement of imaging technology, systemic disease control rate and survival rate, the morbidity of brain metastases (BMs) from non-small cell lung cancer (NSCLC) has been riding on a steady upward trend (40%), but management of BMs from NSCLC remains obscure. Systemic therapy is anticipated to offer novel therapeutic avenues in the management of NSCLC BMs, and radiotherapy (RT) and immunotherapy have their own advantages. Recently, it was confirmed that immune checkpoint inhibitors (ICIs) and RT could mutually promote the efficacy in the treatment of BMs from NSCLC. In this paper, we provide a review on current understandings and practices of separating or combining ICIs and RT, which could provide a reference for the coming laboratory and clinical studies and contribute to the development of new approaches in NSCLC BMs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.